首页|ctDNA检测在非小细胞肺癌临床诊疗应用中的最新研究进展

ctDNA检测在非小细胞肺癌临床诊疗应用中的最新研究进展

扫码查看
非小细胞肺癌(non-small cell lung cancer,NSCLC)是一种高度致死性的恶性肿瘤,给人类健康带来严重威胁.传统的肿瘤诊疗方法存在许多局限性,而液体活检技术中的循环肿瘤DNA(circulating tumor DNA,ctDNA)检测由于其无创便捷、全面灵敏的特点,在NSCLC的个体化治疗和监测中引起了广泛关注.该文将综述近年来ctDNA检测在NSCLC临床诊疗应用中的最新研究进展,包括其在早期筛查、疾病诊断、肿瘤突变监测、治疗效果评估以及预后评估等方面的应用.
Latest Research Progress in ctDNA Detection for Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer
Non-small cell lung cancer(NSCLC)is a highly lethal malignant tumor that poses a serious threat to human health.Traditional methods for tumor diagnosis and treatment have many limitations.However,circulating tumor DNA(ctDNA)detection,a kind of liquid biopsy technology,has gained widespread attention in the field of NSCLC personalized therapy and monitoring due to its non-invasive,convenient,and comprehensive sensitivity.This article will review the latest research progress of ctDNA detection in the clinical diagnosis and treatment of NSCLC in recent years,including its applications in early screening,disease diagnosis,tumor mutation monitoring,treatment efficacy evaluation,and prognosis assessment.

non-small cell lung cancerliquid biopscirculating tumor DNA

梁佐、仝志强、岳振华、白晓鸣

展开 >

山西医科大学第五临床医学院,太原 030012

山西省人民医院,太原 030012

非小细胞肺癌 液态活检 循环肿瘤DNA

2024

现代检验医学杂志
陕西省临床检验中心,陕西省人民医院

现代检验医学杂志

CSTPCD
影响因子:0.713
ISSN:1671-7414
年,卷(期):2024.39(2)
  • 42